Harmony Biosciences Holdings, Inc. (HRMY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Harmony Biosciences Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Harmony Biosciences Holdings, Inc. (HRMY) has returned -25.15% so far this year and -15.61% over the past 12 months.

Based on dividend-adjusted daily data since Aug 19, 2020, HRMY's average daily return is +0.04%, while the average monthly return is +0.42%. At this rate, your investment would double in approximately 13.8 years.

Historically, 50% of months were positive and 50% were negative. The best month was Aug 2021 with a return of +29.6%, while the worst month was Oct 2023 at -28.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, HRMY closed higher 48% of trading days. The best single day was Oct 31, 2023 with a return of +19.4%, while the worst single day was Oct 13, 2023 at -30.3%.

Harmony Biosciences Holdings, Inc. has an annualized alpha of -1.82%, beta of 0.85, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since August 20, 2020.

• This stock participated in 142.58% of S&P 500 Index downside but only 73.62% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HRMY ranks 24 for risk / return — below 24% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Harmony Biosciences Holdings, Inc. (HRMY) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Harmony Biosciences Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Harmony Biosciences Holdings, Inc. was 68.48%, occurring on Oct 27, 2023. The portfolio has not yet recovered.

The current Harmony Biosciences Holdings, Inc. drawdown is 54.01%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Harmony Biosciences Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Harmony Biosciences Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.